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Acute pancreatitis is the most common and feared adverse event associated with 
performance of endoscopic retrograde cholangiopancreatography (ERCP). Un-
remitting effort has been made for over 40 years to minimize the frequency and 
severity of this complication. Recently, the use of rectal non-steroidal anti-in-
flammatory drugs (NSAIDs) have opened a new era for its prevention. This review 
focuses on the role of NSAIDs in pancreatitis, the pharmacokinetics of these 
agents, and summarizes the results of clinical trials with rectal NSAIDs alone 
and combination regimens in the prevention of post-ERCP pancreatitis.
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INTRODUCTION
Acute pancreatitis is the most common 
and arguably most feared adverse event 
related with endoscopic retrograde 
cholangiopancreatography (ERCP) [1,2]. 
The frequency of post-ERCP pancreati-
tis (PEP) has been reported to be 3.4% 
to 6.0% in average-risk groups [3,4] and 
8% to 13.1% in high-risk groups [4,5], 
resulting in significant morbidity and 
mortality [6,7].
Since 1977, when clinical trials using 
aprotinin [8] and calcitonin [9] were 
reported, more than 35 pharmacologic 
agents have been evaluated for the pre-
vention of PEP, with several different 
mechanisms of action. However, most 
of those pharmacologic agents have 
shown no consistent benefit or ques-
tionable efficacy for PEP prevention.
Recently, rectally administered 
non-steroidal anti-inflammatory 
drugs (NSAIDs; indomethacin and di-
clofenac) were determined to be poten-
tially effective in the prevention of PEP 
in both low- and high-risk patients 
[10-13] and ultimately a landmark trial 
in high-risk patients showed a 46% 
relative risk (RR) reduction of PEP with 
rectally administered indomethacin [5]. 
However, the preventive effect of rectal 
NSAIDs on PEP is suboptimal since 
PEP continues to occur with rectal 
NSAIDs in certain patients. Therefore, 
novel trials with a combination of rec-
tal NSAIDs and other pharmacologic 
agents have been conducted.
In this review, the role of NSAIDs 
in pancreatitis, pharmacokinetics of 
rectal NSAIDs, and results of clinical 
trials with rectal NSAIDs alone and 
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combination regimens in PEP prevention will be re-
viewed and summarized.
PATHOPHYSIOLOGY OF PEP
The causes of PEP are multi-factorial. Both patient- 
and procedure-related factors induce various inciting 
events that may cause mechanical obstruction from 
edematous trauma of the pancreatic sphincter, increase 
pancreatic ductal pressure or stimulate spasm of the 
sphincter of Oddi. These inciting events finally lead to 
a common vicious inflammatory cycle of inappropriate 
activation of pancreatic enzymes and auto-digestion [14].
ROLE OF NSAIDs IN PANCREATITIS
An inducible form of cyclooxygenase-2 (COX-2) has been 
implicated as an important proinflammatory mediator 
[15]. COX-2 is up-regulated in response to a variety of 
pro-inflammatory stimuli including interleukin 1, tu-
mor necrosis factor α, and bacterial lipopolysaccharide 
[16-18]. COX-2 mRNA and protein levels are increased 
during experimental pancreatitis [19]. Inhibition of 
COX-2 by either pharmacologic inhibition or selective 
genetic deletion markedly attenuated the severity of 
acute pancreatitis in animal models, suggesting that 
COX-2 plays as an important pro-inflammatory regula-
tor of the severity of pancreatitis [19]. 
The hypothetical mechanism of COX-2 inhibition 
in ameliorating experimental pancreatitis may involve 
two distinct pathways [20]. The direct effect of COX-2 
inhibition is the reduction in prostaglandin synthesis, 
which promotes edema formation and vascular chang-
es, in pancreas and serum [21-23]. COX-2 inhibition 
may also suppress the activation of transcription factor 
nuclear factor κB (NF-κB), which plays an important 
role in proinflammatory cytokine expression [22,24]. 
However, some experimental studies failed to demon-
strate inhibition of the NF-κB activation with the COX-
2 inhibitor (celecoxib) [22]. Two human case-control 
studies evaluated the association with oral COX-2 in-
hibitors and other NSAIDs including diclofenac and in-
domethacin [25,26]. The adjusted odds ratios (ORs) for 
acute pancreatitis were 1.4 (95% confidence interval [CI], 
1.0 to 2.0) to 5.62 (95% CI, 3.33 to 9.45) for current COX-
2 selective inhibitor (celecoxib), and 3.6 (95% CI, 3.33 to 
9.45) for indomethacin and 5.0 (95% CI, 3.33 to 9.45) for 
diclofenac, respectively, compared with controls. These 
data suggest that the cumulative or simultaneous use of 
COX-2 inhibitors and NSAIDs may increase the risk of 
acute pancreatitis.
WHY ONLY RECTAL NSAIDs ARE EFFECTIVE 
FOR PEP
Indomethacin and diclofenac follow linear pharma-
cokinetics. Plasma concentration and area under the 
curve are proportional to the dose administered, where-
as half-life (T ½) and plasma and renal clearance are 
not dose-dependent. Indomethacin and diclofenac are 
both rapidly absorbed from the gastrointestinal tract 
and following oral administration have virtually 90% to 
100% bioavailability, with peak plasma concentrations 
following a single dose occurring between one and 
1.5 hours in the fasting state [27-29]. In contrast, peak 
plasma concentration of indomethacin occurred 40 
minutes after intramuscular injection and 60 minutes 
after rectal suppository. The bioavailability after rectal 
suppository was about 80% [30,31].
Oral (two doses given 6 hours apart) [32,33] and in-
tramuscular administration [34] of diclofenac have not 
shown a protective effect on PEP. Why are these meth-
ods of administration not effective in PEP prevention 
when the bioavailability is more than 90% in both in-
stances? Diclofenac undergoes first-pass metabolism (a 
phenomenon of drug metabolism whereby the concen-
tration of a drug is greatly reduced before it reaches the 
systemic circulation) with only 50% to 60% of the drug 
reaching the systemic circulation as intact diclofenac 
[29,35]. In contrast, as indomethacin is not subject to 
significant first-pass metabolism, oral indomethacin 
potentially may exert a preventive effect on PEP. 
What is the specific mechanism by which rectal in-
domethacin demonstrates its preventive effect on PEP? 
Peak plasma concentration is achieved in 90 minutes 
after rectal indomethacin, but this peak plasma concen-
tration is sustained for more than 2 hours and decreas-
es slowly, compared to intravascular and intramuscu-
lar administration (Fig. 1) [31]. Based on the previous 
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reports that have demonstrated a consistent beneficial 
effect of rectal indomethacin on the prevention of PEP, 
this sustained plasma concentration may play a key role 
in the prevention of PEP. The correlation between its 
preventive effect and high sustained plasma concen-
tration needs to be further evaluated by measuring the 
plasma concentration at various time points after rectal 
indomethacin in clinical practice. Potentially, the veiled 
hypothetical mechanism for prevention of PEP may be 
further elucidated. Furthermore, these pharmacokinet-
ic data may guide the design of new studies with indo-
methacin and PEP prevention.
ADMINISTRATION AND TIMING OF RECTAL 
NSAIDs
Rectal NSAIDs have been administered at different 
time points in previous clinical trials according to the 
optimal pharmacokinetics of rectal NSAIDs assumed by 
the individual researchers, varying from 5 hours before 
ERCP to immediately after ERCP.
In two meta-analyses, the optimal timing of adminis-
tration of rectal NSAIDs was evaluated [36,37]. The first 
meta-analysis showed that rectal NSAIDs administered 
before ERCP lowered the risk of PEP with statistical 
significance (RR, 0.48; 95% CI, 0.29 to 0.78; p = 0.003) 
[36]. In contrast, the second meta-analysis showed the 
efficacy of rectal indomethacin or diclofenac for PEP 
prevention did not differ whether the NSAIDs were ad-
ministered before or after ERCP (RR, 0.54; 95% CI, 0.42 
to 0.70; p = 0.99) [37].
In a recent trial of 162 patients, double dose rectal in-
domethacin (200 mg) was administered as 100 mg at 4.5 
hours before and 100 mg immediately after ERCP and 
compared with a single 100 mg dose given immediately 
after ERCP [38]. In the 42 patients deemed to be at high 
risk for pancreatitis, there was no significant reduction 
in PEP with the double dose (single dose 9.5%, n = 2; 
double dose 4.8%, n = 1; p = 0.24). 
Considering the peak plasma concentration of indo-
methacin is 90 minutes after rectal administration, and 
no benefit of early administration (i.e., 4 hours) pre-ER-
CP, we believe that the optimal timing for rectal NSAID 
administration might be 90 minutes before starting the 
ERCP, but further study is warranted.
OVERALL PROPHYLACTIC EFFECT
The frequency of PEP before the widespread admin-
istration of rectal NSAIDs (in 2012) was reported to 
be 9.7% (95% CI, 8.6% to 10.7%) in a meta-analysis of 
randomized placebo-controlled trials (RCT) [7]. The fre-
quency of PEP among 10,591 patients from 94 non-risk 
stratified RCTs was 8.5% (95% CI, 7.4% to 9.5%). In 22 
RCTs (with 2,345 patients) where risk stratification was 
performed, the frequency of PEP in high-risk patients 
was 14.7% (95% CI, 11.8% to 17.7%). In addition, the fre-
quency of moderate and severe PEP in the high-risk 
subgroup was reported to be 3.9% (95% CI, 2.6% to 5.3%) 
and 0.8% (95% CI, 0.3% to 1.2%), respectively.
In an analysis of 24 prospective RCTs using rectal 
NSAIDs for PEP prevention, the frequency of PEP 
among 7,798 patients who were administered with 
rectal NSAIDs was 6.3% (95% CI, 5.7% to 6.8%) (unpub-
lished extracted data). The frequency of PEP among 5,431 
average-risk patients from 17 RCTs was 5.7% (95% CI, 
5.1% to 6.3%). The frequency of PEP among 1,661 high-
risk patients from seven RCTs was 7.2% (95% CI, 5.9% 
to 8.4%). Among all 7,798 patients, the rate of moder-
ate-to-severe PEP was 1.3% (95% CI, 1.0% to 1.5%) (Table 
1). Rectal NSAIDs significantly reduced the frequency 
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Figure 1. Plasma concentration profile of indomethacin in 
eight human subjects following four different administra-
tions. Adapted from Jensen et al. [31], with permission from 
John Wiley and Sons. IV, intravenous; IM, intramuscular.
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of PEP with a RR of 0.53 (95% CI, 0.44 to 0.63; p < 0.001) 
according to a meta-analysis of 21 RCTs with 6,134 pa-
tients [39].
PROPHYLACTIC EFFECT ACCORDING TO RISK 
STRATIFICATION 
Although the prophylactic effect of rectal indomethacin 
on PEP was seen in high-risk patients in a landmark 
study [5], controversies in prophylactic effect remain as 
to whether the same benefit is seen across patient risk 
stratification. Specially, are rectal NSAIDs indicated for 
PEP prophylaxis in low-risk patients?
In an RCT of 449 consecutive patients, a single 100 
mg dose of rectal indomethacin during ERCP did not 
prevent PEP. However, approximately 70% of the en-
rolled patients were at average risk for developing PEP 
[40]. Pancreatitis occurred in 16 of 223 patients (7.2%) 
in the indomethacin group and 11 of 226 (4.9%) in the 
placebo group (p = 0.33). In contrast, a retrospective 
cohort study of 4,017 patients, including low-risk pa-
tients (mostly those with malignant biliary obstruction), 
showed that post-procedural rectal indomethacin ad-
ministration was associated with a significant decrease 
in the absolute rate and severity of PEP [3]. The overall 
frequency of PEP was reduced from 4.7% to 2.0% (OR, 
0.35; 95% CI, 0.24 to 0.51; p < 0.001) and moderate-to-se-
vere PEP from 2.7% to 0.6% (OR, 0.17; 95% CI, 0.09 to 
0.32; p < 0.001).
Two meta-analyses have addressed the question 
whether there is a difference in prevention of PEP 
with rectal NSAIDs when evaluating average-risk and 
high-risk patients [37,41]. In one meta-analysis, rectal 
indomethacin was found to be protective against PEP 
in high-risk patients (RR, 0.43; 95% CI, 0.28 to 0.65; 
p < 0.001) but not average-risk patients (RR, 0.74; 95% 
CI, 0.52 to 1.07; p = 0.115) [41]. The other meta-analysis 
showed that the efficacy of diclofenac or indomethacin 
was significant both in the high-risk group (RR, 0.53; 
95% CI, 0.29 to 0.97; p = 0.038) and the average-risk 
group (RR, 0.63; 95% CI, 0.46 to 0.86; p = 0.003). The dif-
ference between the high-risk and average-risk patients 
was not significant (p = 0.69). The number needed to 
treat was 13 in the high-risk group and 27 in the aver-
age-risk group [37].
DOSE OF RECTAL NSAIDs: LOW VS. SINGLE VS. 
DOUBLE DOSE
The majority of published clinical trials to date have 
been conducted with a single 100 mg dose of rectal in-
domethacin or diclofenac. 
A trial from Japan evaluated the efficacy of low-dose 
(50 mg) rectal diclofenac [42]. The frequency of PEP was 
significantly lower with the low-dose rectal diclofenac 
than the control group (3.9% [2/51] vs. 18.9% [10/53], p = 
0.017). In this trial, dose reduction to 25 mg was per-
formed in patients weighing < 50 kg. There was no sig-
nificant difference in the frequency of PEP between the 
25 and 50 mg groups as well (9% [2/22] vs. 0% [0/29], p 
= 0.101). Considering a lower mean body weight of this 
Japanese population, low-dose 50 mg of rectal NSAID 
Table 1. Trend in the frequency of post-ERCP pancreatitis
Variable
Before widespread administration of 
rectal NSAIDs
24 Randomized controlled trials using 
rectal NSAIDs
Total no. of patients 13,296 7,798
Frequency of PEP, % 9.7 6.3 
Non-risk stratified (average-risk) group 8.5 5.7 
High-risk group 14.7 7.2 
Moderate-to-severe PEP, % 4.7a 1.3b
ERCP, endoscopic retrograde cholangiopancreatography; NSAID, non-steroidal anti-inflammatory drug; PEP, post-endoscopic 
retrograde cholangiopancreatography pancreatitis.
aIn high-risk group.
bAmong all 7,798 patients.
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may be effective for PEP prevention in similar patient 
populations.
Recently, two randomized clinical trials with dose 
escalation of rectal indomethacin to 200 mg were re-
ported [38,43]. It was hypothesized that a higher dose 
might be superior to the existing standard 100 mg dose 
in PEP prevention. Split dose administration was per-
formed in both studies: to minimize the potential for 
adverse events of the higher dose in one study [38], and 
to potentially lead to a higher peak serum concentra-
tion and a more sustained impact on the inflammatory 
cascade in the second study [43]. In the first trial from 
Taiwan, which evaluated predominantly average-risk 
patients, the double dose group received an initial 100 
mg about 4 to 5 hours before ERCP and an additional 
100 mg immediately after ERCP [38]. In the second tri-
al, a multicenter trial from USA which evaluated only 
patients who were considered to be at high-risk for the 
development of PEP, the high-dose group received an 
initial 150 mg at the end of the ERCP, followed by an 
additional 50 mg 4 hours after the procedure [43]. In 
both studies, dose escalation of rectal indomethacin to 
200 mg did not confer any additional reduction in PEP. 
COMBINATION WITH OTHER 
PHARMACOLOGICAL AGENTS
Administration of a rectal NSAID at ERCP has led to a 
significant reduction in frequency and severity of PEP, 
particularly in high-risk patients. While this discovery 
has been a major breakthrough in ERCP, PEP remains 
a significant concern, and cases of severe PEP continue 
to occur, albeit at a reduced rate. Clearly, the only fool-
proof method to prevent PEP is to not proceed with the 
procedure. Additional study is needed to further lower 
PEP rates. In addition to studies evaluating a higher 
dose of the NSAID (i.e., double dose) as described above 
[38,43], trials with combination rectal NSAIDS and other 
strategies or pharmacologic agents including intrave-
nous fluids [44-46], intravenous somatostatin [47], sub-
lingual isosorbide dinitrate [48,49], and intraduodenal 
epinephrine spray [50-52] have been reported (Table 2).
One trial evaluated the preventive efficacy for PEP 
with the combination of rectal diclofenac and intra-
venous somatostatin [47]. With this combination, the 
frequency of PEP significantly decreased compared 
with placebo (12/255 [4.7%] vs. 27/260 [10.4 %], p = 0.015). 
This benefit was confined to those patients considered 
to be at high-risk for PEP (11/188 [5.8%] vs. 25/203 [12.3%], 
p = 0.027), with no benefit noted in the low-risk group 
(1/67 [1.5%] vs. 2/57 [3.5%], p = 0.594). While it would be of 
interest to know the PEP rates of patients who received 
either diclofenac or somatostatin (but not both) in this 
patient population, in order to better assess the efficacy 
of the combination therapy, no patient received single 
drug therapy in this study.
There were three trials that evaluated with combi-
Table 2. Summary of randomized controlled trials
Regimens No. of  RCTs Results
NSAIDs alone
Oral 2 Not efficacious
Intravenous 2 Not efficacious
Intramuscular 4 Efficacious in 2 of 4 RCTs
Rectal, single/double dose 14/2 Efficacious, but no additional 
   benefit with double dose
Combination regimens
Rectal diclofenac + IV somatostatin 1 Efficacious
Rectal indomethacin + IV hydration 3 Efficacious
Rectal indomethacin + intraduodenal epinephrine spray 3 Not efficacious in 2 of 3 RCTs
Rectal NSAIDs + sublingual nitrate 2 Efficacious
RCT, randomized controlled trial; NSAID, non-steroidal anti-inflammatory drug; IV, intravenous.
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nation of rectal NSAIDs and aggressive intravenous 
hydration of normal saline [44] and lactated Ringer’s 
solution [45,46]. Three trials consistently showed that 
the frequency of PEP was significantly lower with the 
combination of rectal NSAIDs and aggressive hydration 
compared with placebo (0% to 6% vs. 2.7% to 21%).
Two clinical trials evaluated the preventive efficacy 
for PEP with the combination of rectal NSAIDs and 
sublingual isosorbide dinitrate [48,49]. Both trials 
showed that the frequency of PEP was significantly low-
er with the combination therapy compared with rectal 
NSAIDs alone (6.7% vs. 15.3% [48] and 5.6% vs. 9.5% [49]).
Three clinical trials were conducted with the combi-
nation of rectal indomethacin and topical epinephrine 
sprayed on the major papilla, based on the results of a 
previous network meta-analysis [50-53]. In the first trial, 
the frequency of PEP was significantly lower with the 
combination regimen compared with rectal indometh-
acin alone (0% vs. 9%) [50]. However, in the subsequent 
two large-scale trials, the frequency of PEP with the 
combination regimen was not significantly different 
compared with rectal indomethacin alone (6.7% to 8.5% 
vs. 5.3% to 6.4%) [51,52]. Overall, there does not appear 
to be any additional benefit to epinephrine spray with 
reduction in PEP in patients receiving rectal indometh-
acin [54].
ADDITIONAL PANCREATIC DUCT STENT
Several randomized, controlled trials and meta-anal-
yses have proven a significant reduction in frequency 
and severity of PEP with prophylactic pancreatic duct 
stent placement [55,56]. However, indomethacin signifi-
cantly reduced the risk of PEP regardless of pancreatic 
duct stent placement (among patients with a pancreatic 
stent, from 16.1% to 9.7%; patients without a pancreatic 
stent, from 20.6% to 6.3%) [5]. In addition, a network 
meta-analysis has shown that rectal NSAIDs alone are 
superior to pancreatic duct stents in preventing PEP 
with a pooled odd ratio of 0.48 (95% CI, 0.26 to 0.87) [57]. 
Considering the increased technical demands of pan-
creatic duct stent placement (familiarity with smaller 
caliber guidewires, ansa pancreatica anatomy, etc.) even 
when performed by experienced endoscopists, further 
study is needed to clarify whether additional pancreatic 
duct stent placement may be recommended in certain 
situations (e.g., unintentional cannulation of the pan-
creatic duct in biliary cases). An ongoing clinical trial 
will clarify the additional prophylactic role of a pancre-
atic duct stent in high-risk patients [58].
SUGGESTED RECOMMENDATIONS
Current literature clearly demonstrates a reduction in 
PEP with rectal NSAIDs in high-risk patients, with a 
benefit in average- or low-risk patients less clear. How-
ever, given the relatively low cost, ease of administra-
tion and safety profile of rectal NSAIDs, it is reasonable 
to administer rectal NSAIDs to all patients undergoing 
ERCP. Furthermore, aggressive intravenous fluid ad-
ministration should be provided. An additional second 
(or third) agent such as sublingual nitrate or intrave-
nous somatostatin could be considered for high-risk 
patients.
CONCLUSIONS
Rectal NSAIDs have definitely opened a new era for 
the prevention of PEP. However, further studies to 
decrease its incidence and to attenuate the severity are 
warranted. 
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